Geneva, Nov. 3 -- International Clinical Trials Registry received information related to the study (ACTRN12625001167459) titled 'HILINER: Randomised Control Trial to determine the optimal dosing of radioactive iodine dosing in Intermediate/High risk papillary thyroid cancer' on Oct. 24.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Primary Sponsor: Northern Sydney Local Health District
Condition:
thyroid cancer
thyroid cancer
Cancer - Thyroid
Intervention:
- 1 GBq of radioactive iodine (RAI) for intermediate- or high-risk BRAF-positive papillary thyroid cancer, with no evidence of persistent or metastatic disease. RAI is administered orally as a single dose.
- Treatment admin...